Imugene Ltd (ASX:IMU, OTC:IUGNF) has released its quarterly report for the period ending June 30, 2025, highlighting clinical advancements and strengthened funding to support its immuno-oncology programs.
Positive azer-cel results in Phase 1b trial
The company reported encouraging clinical data from its Phase 1b trial of azer-cel, with six patients achieving Complete Responses and three Partial Responses, translating to a 75% Overall Response Rate. These findings underscore the potential of azer-cel in treating advanced malignancies.
OASIS trial progresses with IV dose clearance
In the OASIS Phase 1 clinical trial evaluating the onCARlytics platform, Imugene confirmed the successful clearance of the first intravenous (IV) dose level in the combination arm. This marks a significant step forward in assessing the safety and efficacy of this novel treatment modality.
Neo-POLEM Phase II trial begins dosing in Australia
The first patient has been dosed in the Phase II Neo-POLEM clinical trial of PD1-Vaxx at the Queen Elizabeth Hospital in Adelaide. The trial aims to evaluate PD1-Vaxx in combination with chemotherapy and immunotherapy in patients with colorectal cancer.
Strengthening intellectual property portfolio
Imugene has bolstered its IP position with the issuance of a United States patent for the onCARlytics platform and an extension of its US patent for PD1-Vaxx, reinforcing its innovation pipeline in the cancer immunotherapy space.
Leadership and capital developments post quarter-end
Dr John Byon was appointed Chief Medical Officer, bringing a wealth of experience in clinical development and immuno-oncology.
Post quarter-end, Imugene completed a A$22.5 million placement and received a A$5.8 million R&D tax refund for FY24, with a Share Purchase Plan targeting approximately A$15 million underway.